CARM1 inhibition using TP-064 reduced the proliferation of DLBCL cells which was most effective when these cells carried inactivating mutations in genes encoding the HATs CBP or p300 [167]. The gene discussed is CARM1; the disease is diffuse large B-cell lymphoma.